Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified
Open Access
- 1 July 2018
- journal article
- Published by Weston Medical Publishing in Journal of Opioid Management
- Vol. 14 (4) , 295-303
Abstract
Objective: Urine drug testing (UDT) is increasingly performed as a means of identifying aberrant behavior that may be grounds for discontinuation of long-term opioid therapy (LTOT). Little is known, however, about the ways in which positive UDT results may differentially inform decisions to discontinue LTOT based on the type of substance for which the UDT screened positive. The aim of this study was to examine the likelihood of clinician-initiated discontinuation of LTOT attributed to positive UDT results across three discrete categories of substances: (1) cannabis, (2) alcohol or illicit substances (excluding cannabis), and (3) controlled prescription medications that were not prescribed.Design: This retrospective study utilized the US Department of Veterans Affairs (VA) Health Care System. Corporate Data Warehouse to assemble a sample of 600 patients with substance use disorders and matched controls who were discontinued from LTOT in 2012. Comprehensive manual medical record review identified UDT results in the year prior to discontinuation and reason(s) for discontinuation.Patients, Participants: Patients with one or more UDTs positive for a single substance (N = 185) comprised the study sample.Main Outcome Measure(s): Likelihood of clinician-initiated discontinuation attributed to a positive UDT across the three categories. Results: Patients with one or more UDTs positive for cannabis were more likely to be discontinued from opioid therapy as a result of the positive UDT compared to those with one or more UDTs positive for nonprescribed prescription medication (adjusted odds ratio [OR] = 18.05, 95% CI = 7.29-44.66). Similarly, patients with UDTs positive for alcohol or illicit substances were more likely to be discontinued for the positive UDTs relative to patients who tested positive for nonprescribed prescription medications (adjusted OR = 13.10, 95% CI = 4.81-35.68). No difference in UDT-related discontinuation decisions was evident between patients with UDTs positive for alcohol/illicit substances versus cannabis (adjusted OR = 1.47, 95% CI = 0.57-3.77). Conclusions: High odds of UDT-related discontinuation were found in patients who tested positive for cannabis, alcohol, or illicit substances, relative to nonprescribed prescription medications.Keywords
This publication has 28 references indexed in Scilit:
- The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention WorkshopAnnals of Internal Medicine, 2015
- National study of discontinuation of long-term opioid therapy among veteransPain, 2014
- Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010JAMA Internal Medicine, 2014
- They Don’t Know What They Don’t Know: Internal Medicine Residents’ Knowledge and Confidence in Urine Drug Test Interpretation for Patients with Chronic PainJournal of General Internal Medicine, 2012
- A Review of Potential Adverse Effects of Long-Term Opioid TherapyThe Primary Care Companion For CNS Disorders, 2012
- Long-Term Chronic Opioid Therapy Discontinuation Rates from the TROUP StudyJournal of General Internal Medicine, 2011
- Documentation of Pain Care Processes Does Not Accurately Reflect Pain Management Delivered in Primary CareJournal of General Internal Medicine, 2009
- Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer PainThe Journal of Pain, 2009
- Urine Drug Screening: Practical Guide for CliniciansMayo Clinic Proceedings, 2008
- Pain Clinicians' Rankings of Aberrant Drug-Taking BehaviorsJournal of Pain & Palliative Care Pharmacotherapy, 2002